Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 6/20 | 0.60 |
| ▸ | CACNB1 | Q02641 | 6/20 | 0.60 |
| ▸ | CACNA1B | Q00975 | 5/20 | 0.60 |
| ▸ | CACNA1C | Q13936 | 3/20 | 0.60 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.60 |
| ▸ | MGLL | Q99685 | 3/20 | 0.59 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.59 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | TACR3 | P29371 | 1/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.57 |
| ▸ | DRD3 | P35462 | 2/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.57 |
| ▸ | HTR1A | P08908 | 1/20 | 0.57 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.57 |
| ▸ | BCL2 | P10415 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17276580 | 0.95 | MGLL (0.64) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1G | |
| SCHEMBL4013471 | 0.92 | KMT2A (0.67) | CACNA2D1CACNB1CACNA1BCACNA1CMGLL | |
| SCHEMBL6797094 | 0.88 | KMT2A (0.58) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1G | |
| SCHEMBL13309487 | 0.86 | CACNA2D1 (0.67) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1G | |
| SCHEMBL14367531 | 0.85 | CACNA2D1 (0.54) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1G | |
| SCHEMBL6792134 | 0.84 | OPRD1 (0.63) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1G | |
| SCHEMBL12371643 | 0.84 | MEN1 (0.56) | MGLLABHD6KMT2AMEN1CYP3A4 | |
| SCHEMBL14051945 | 0.82 | GPX4 (0.54) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1G | |
| SCHEMBL12203725 | 0.82 | MGLL (0.84) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1G | |
| SCHEMBL4136263 | 0.82 | SLC6A9 (0.63) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963296-B1 | OPTICALLY ACTIVE CARBAMATES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS PHARMACEUTICAL INTERMEDIATES | EGIS GYOGYSZERGYAR NYILVANOSAN MUKOEDOE RESZVENYTARSASAG (HU) | 2012-02-15 | — | — | EP | disclosed |
| US-7851627-B2 | Optically active carbamates, process for preparation thereof and use thereof as pharmaceutical intermediates | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2010-12-14 | — | — | US | disclosed |
| US-7851627-B2 | Optically active carbamates, process for preparation thereof and use thereof as pharmaceutical intermediates | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2010-12-14 | — | — | US | disclosed |
| US-20090221823-A1 | OPTICALLY ACTIVE CARBAMATES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS PHARMACEUTICAL INTERMEDIATES | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2009-09-03 | — | — | US | disclosed |
| US-20090221823-A1 | OPTICALLY ACTIVE CARBAMATES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS PHARMACEUTICAL INTERMEDIATES | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2009-09-03 | — | — | US | disclosed |
| WO-2007066163-A2 | OPTICALLY ACTIVE CARBAMATES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS PHARMACEUTICAL INTERMEDIATES | Egis Gyógyszergyár Nyilvanosan Mukodo Reszvenytarsasag (HU) | 2007-06-14 | — | — | WO | disclosed |
| EP-1236722-B1 | Optically active 4-(tert-butoxycarbonyl) piperazine compound, and method for producing the same | SUMITOMO CHEMICAL CO (JP) | 2006-04-19 | — | — | EP | disclosed |
| US-6803465-B2 | INTERMEDIATES FOR THE PRODUCTION OF ANTIALLERGIC PHARMACEUTICALS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-10-12 | — | — | US | disclosed |
| US-20020128275-A1 | Optically active 4-(tert-butoxycarbonyl)piperazine compound, and method for producing the same | SUMITOMO CHEMICAL COMPANY, LIMITED | 2002-09-12 | — | — | US | disclosed |
| EP-1236722-A1 | Optically active 4-(tert-butoxycarbonyl) piperazine compound, and method for producing the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128275-A1 | Optically active 4-(tert-butoxycarbonyl)piperazine compound, and method for producing the same | TERT, TTI1, TBC1D15 | CACNA2D1 1002/4885CACNB1 1139/4885CACNA1B 346/4885 |
| US-20090221823-A1 | OPTICALLY ACTIVE CARBAMATES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS PHARMACEUTICAL INTERMEDIATES | HRH4, HRH1, HRH2 | CACNA2D1 1056/4885CACNB1 2856/4885CACNA1B 1411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.